Please login to the form below

Not currently logged in
Email:
Password:

breast cancer

This page shows the latest breast cancer news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

There was some slippage for immunology drug MabThera/Rituxan (rituximab) and Herceptin (trastuzumab) for breast cancer, with the declines seen most starkly in Europe where they fell 38% and 44% respectively. ... It’s looking likely to overtake

Latest news

  • NICE says no to Novartis’ Kisqali combo in breast cancer NICE says no to Novartis’ Kisqali combo in breast cancer

    Double blow after Lilly rival recommended. Novartis’ hopes of a boost for under-performing breast cancer drug Kisqali have been hit by a negative verdict from NICE. ... receptor-positive, HER2-negative, locally advanced or metastatic breast cancer who

  • Lynparza set for further expansion with EU approval in breast cancer Lynparza set for further expansion with EU approval in breast cancer

    There were an estimated 2.1m new cases of breast cancer worldwide last year, and around 30% of women diagnosed with early breast cancer will go on to develop advanced disease. ... The OlympiAD trial supported the approval, and showed Lynparza produced an

  • AZ makes $6.9bn play for Daiichi Sankyo HER2 drug AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

    Notably, it is also in a phase 3 trial in breast cancer patients whose tumours have lower levels of HER2 expression. ... breast cancer which collectively added more than $3bn to the company’s top-line last year.

  • CHMP recommends new Keytruda dosing schedule CHMP recommends new Keytruda dosing schedule

    It made history by becoming the first FDA-approved drug specifically for advanced CSCC, a type of skin cancer. ... It most recently gained the first immuno-oncology approval in triple negative breast cancer, claiming an advantage over Keytruda, which has

  • Gottlieb admonishes industry for clinical trial failings Gottlieb admonishes industry for clinical trial failings

    Gottlieb – who is leaving the FDA next month and will be replaced on an interim basis by National Cancer Institute (NCI) director Ned Sharpless – says that the advent in precision medicine, ... study of neoadjuvant and personalised drugs for breast

More from news
Approximately 98 fully matching, plus 635 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    People who have BRCA gene mutations have an increased risk of certain cancers, including breast cancer, ovarian cancer and prostate cancer. ... We’re starting to see that we can make the same progress in lung cancer that we’ve made in breast cancer.

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... Breast cancer drug Ibrance will be one of the biggest growth drivers for the company, as it looks

  • 30 Women Leaders in UK Healthcare (part 3) 30 Women Leaders in UK Healthcare (part 3)

    policy campaigning and research, and putting breast cancer firmly on the public agenda. ... kind. Its stated ambition is that, by 2050, everyone who develops breast cancer will live.

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2

  • The tipping point The tipping point

    In 2016 alone, there were approximately 30 oncology drugs in late stage development for breast cancer, leukaemia, lung cancer and ovarian cancer.

More from intelligence
Approximately 1 fully matching, plus 58 partially matching documents found.

Latest appointments

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    cancer programme, associate director for strategic relations for the Duke Cancer Institute among other roles. ... cancer research, especially metastatic breast cancer, where she has led programmes that resulted in numerous ground-breaking regulatory

  • Ipsen boosts specialty care and R&D leadership teams Ipsen boosts specialty care and R&D leadership teams

    Prior to this, he served as executive director and breast cancer lead for US oncology medical affairs, and held a number of medical affairs oncology positions at Novartis and Bayer.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Agendia appoints chairman of medical advisory board Agendia appoints chairman of medical advisory board

    Dr Hortobagyi brings over 35 years of experience in clinical and translational research of breast cancer and work as a breast medical oncologist to the molecular cancer diagnostics company. ... He currently also serves as a professor and chair Emeritus

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics